This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Artemotil
- DrugBank Accession Number
- DB13851
- Background
Artemotil, also known as β-arteether, is a semi-synthetic derivative of artemisinin and a fast acting blood schizonticide specifically indicated for the treatment of chloroquine-resistant Plasmodium falciparum malaria and cerebral malaria cases.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Artemotil (DB13851)
- Weight
- Average: 312.406
Monoisotopic: 312.193674002 - Chemical Formula
- C17H28O5
- Synonyms
- Arteether
- Artemotil
- beta-Arteether
- beta-Dihydroartemisinin ethyl ether
- Dihydroartemisinin ethyl ether
- External IDs
- SM 227
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcetophenazine The risk or severity of QTc prolongation can be increased when Artemotil is combined with Acetophenazine. Alimemazine The risk or severity of QTc prolongation can be increased when Artemotil is combined with Alimemazine. Ambroxol The risk or severity of methemoglobinemia can be increased when Artemotil is combined with Ambroxol. Artemether The risk or severity of QTc prolongation can be increased when Artemotil is combined with Artemether. Articaine The risk or severity of methemoglobinemia can be increased when Artemotil is combined with Articaine. Benzocaine The risk or severity of methemoglobinemia can be increased when Artemotil is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Artemotil is combined with Benzyl alcohol. Bupivacaine The risk or severity of methemoglobinemia can be increased when Artemotil is combined with Bupivacaine. Butacaine The risk or severity of methemoglobinemia can be increased when Artemotil is combined with Butacaine. Butamben The risk or severity of methemoglobinemia can be increased when Artemotil is combined with Butamben. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- ATC Codes
- P01BE04 — Artemotil
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- XGL7GFB9YI
- CAS number
- 75887-54-6
- InChI Key
- NLYNIRQVMRLPIQ-XQLAAWPRSA-N
- InChI
- InChI=1S/C17H28O5/c1-5-18-14-11(3)13-7-6-10(2)12-8-9-16(4)20-15(19-14)17(12,13)22-21-16/h10-15H,5-9H2,1-4H3/t10-,11-,12+,13+,14+,15-,16-,17-/m1/s1
- IUPAC Name
- (1R,4S,5R,8S,9R,10S,12R,13R)-10-ethoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0^{4,13}.0^{8,13}]hexadecane
- SMILES
- [H][C@@]12CC[C@@H](C)[C@]3([H])CC[C@@]4(C)OO[C@@]13[C@]([H])(O[C@H](OCC)[C@@H]2C)O4
References
- General References
- Not Available
- External Links
- ChemSpider
- 2272064
- BindingDB
- 50426305
- ChEBI
- 135335
- ChEMBL
- CHEMBL301267
- ZINC
- ZINC000008214360
- Wikipedia
- Artemotil
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.276 mg/mL ALOGPS logP 3.52 ALOGPS logP 3.84 Chemaxon logS -3 ALOGPS pKa (Strongest Basic) -3.9 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 46.15 Å2 Chemaxon Rotatable Bond Count 2 Chemaxon Refractivity 79.41 m3·mol-1 Chemaxon Polarizability 34.08 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created at June 23, 2017 20:49 / Updated at February 21, 2021 18:54